Trial · NCT02770716
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Verified HRS Reversal | Terlipressin | 29.1 | percentage of participants | ||
| Percentage of Participants With Verified HRS Reversal | Placebo | 15.8 | percentage of participants | ||
| Percentage of Participants Who Were Viable (Per Protocol) for Inclusion in the Primary End Point Analysis | Terlipressin | 91.3 | percentage of participants | ||
| Percentage of Participants Who Were Viable (Per Protocol) for Inclusion in the Primary End Point Analysis | Placebo | 94.4 | percentage of participants | ||
| Percentage of Participants With HRS Reversal | Terlipressin | 36.2 | percentage of participants | ||
| Percentage of Participants With HRS Reversal | Placebo | 16.8 | percentage of participants | ||
| Percentage of Participants With Durable HRS Reversal | Terlipressin | 31.7 | percentage of participants | ||
| Percentage of Participants With Durable HRS Reversal | Placebo | 15.8 | percentage of participants | ||
| Percentage pf Participants in the SIRS Subgroup With HRS Reversal | Terlipressin | 33.3 | percentage of participants | ||
| Percentage pf Participants in the SIRS Subgroup With HRS Reversal | Placebo | 6.3 | percentage of participants | ||
| Percentage of Participants With Verified HRS Reversal Without HRS Recurrence by Day 30 | Terlipressin | 24.1 | percentage of participants | ||
| Percentage of Participants With Verified HRS Reversal Without HRS Recurrence by Day 30 | Placebo | 15.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02770716/results